IRAK4在血液系统恶性肿瘤中的作用及其机制研究进展  

Research progress on the role and mechanism of IRAK4 in hematological malignancies

作　　者：商颖 李莉娟[1] 张连生[1] Shang Ying;Li Li-Juan;Zhang Lian-Sheng(Department of Hematology,the Second Hospital of Lanzhou University,Lanzhou,Gansu 730030,China)

机构地区：[1]兰州大学第二医院血液科,甘肃兰州730030

出　　处：《解放军医学杂志》2024年第9期1094-1098,共5页Medical Journal of Chinese People's Liberation Army

基　　金：国家自然科学基金(82360029)。

摘　　要：白细胞介素-1受体相关激酶4(IRAK4)在TLRs/IL-1R信号通路中发挥着关键的信号转导及调控作用,协调涉及免疫系统启动、细胞因子产生和细胞增殖与分化的多种炎症途径,与血液系统恶性肿瘤的发病机制和进展有关,包括骨髓增生异常综合征、急性髓系白血病、慢性淋巴细胞白血病和淋巴瘤等疾病。因此,IRAK4可能为血液系统恶性肿瘤的有效治疗靶点。本文就IRAK4的结构和功能及其在血液系统恶性肿瘤中的作用机制和治疗等方面的研究进展进行综述,旨在为揭示相关疾病的发生机制和靶向治疗研究提供参考。Interleukin-1 receptor associated kinase 4(IRAK4) plays a crucial role in signal transduction and regulation in the TLRs/IL-1R signaling pathway,coordinating multiple inflammatory pathways involving immune system activation,cytokine production,and cell proliferation and differentiation.IRAK4 is associated with the pathogenesis and progression of hematological malignancies,including myelodysplastic syndrome,acute myeloid leukemia,chronic lymphocytic leukemia,and lymphoma.Therefore,IRAK4 may serve as an effective therapeutic target for hematologic malignancies.This review summarizes the research advances in the structure and function of IRAK4,as well as its mechanism of action and therapeutic implications in hematological malignancies,aiming to provide insights into pathogenesis of related diseases and targeted therapy research.

关 键 词：白细胞介素-1受体相关激酶4 血液系统恶性肿瘤 发病机制 靶向治疗 

分 类 号：R733[医药卫生—肿瘤]